ClinConnect ClinConnect Logo
Search / Trial NCT04088071

Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Launched by HEART RHYTHM CLINICAL AND RESEARCH SOLUTIONS, LLC · Sep 10, 2019

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how well a treatment called catheter ablation works for people with two types of heart rhythm problems known as Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PsAF). Catheter ablation is a procedure that uses heat to destroy small areas of heart tissue that may be causing these irregular heartbeats. The goal of the study is to gather real-world information on how effective and safe this treatment is for patients, as well as how smoothly the procedure goes.

To participate in this trial, you must be at least 18 years old and have been diagnosed with either symptomatic Paroxysmal or Persistent Atrial Fibrillation, meaning your heart rhythm problems are causing noticeable symptoms. You should be a candidate for the ablation procedure and be willing to attend follow-up evaluations. However, if you have a more severe form of Atrial Fibrillation that has lasted over a year, or if you're currently in another clinical trial, you might not be eligible. Participants can expect to contribute valuable information that could help improve treatment options for others with similar heart conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) who, in the opinion of the investigator, are candidates for ablation for AF
  • 18 years of age or older
  • De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry
  • Able and willing to participate in baseline and follow up evaluations for the full length of the registry
  • Willing and able to provide informed consent, if applicable
  • Exclusion Criteria:
  • Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
  • Long-standing persistent AF (AF greater than one year's duration)
  • Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry
  • In the opinion of the investigator, any known contraindication to an ablation procedure

About Heart Rhythm Clinical And Research Solutions, Llc

Heart Rhythm Clinical and Research Solutions, LLC is a dedicated organization specializing in the advancement of cardiovascular health through innovative clinical trial management and research initiatives. With a focus on heart rhythm disorders, the company collaborates with healthcare professionals, institutions, and industry partners to design and implement rigorous clinical studies aimed at improving patient outcomes. Leveraging a team of experienced researchers and clinicians, Heart Rhythm Clinical and Research Solutions is committed to fostering scientific discovery and translating findings into effective therapeutic strategies, ultimately enhancing the quality of care for individuals with heart rhythm abnormalities.

Locations

Madison, Wisconsin, United States

Iowa City, Iowa, United States

Portland, Maine, United States

Sarasota, Florida, United States

Royal Oak, Michigan, United States

Columbia, Missouri, United States

Birmingham, Alabama, United States

Savannah, Georgia, United States

Winston Salem, North Carolina, United States

Cincinnati, Ohio, United States

Asheville, North Carolina, United States

Haddon Heights, New Jersey, United States

Ypsilanti, Michigan, United States

Aurora, Colorado, United States

Oklahoma City, Oklahoma, United States

Los Angeles, California, United States

Lancaster, Pennsylvania, United States

Evanston, Illinois, United States

Salt Lake City, Utah, United States

Santa Barbara, California, United States

Rock Hill, South Carolina, United States

Greenville, South Carolina, United States

Naples, Florida, United States

Littleton, Colorado, United States

Atlanta, Georgia, United States

Springfield, Missouri, United States

Winchester, Virginia, United States

York, Pennsylvania, United States

Tacoma, Washington, United States

Lansing, Michigan, United States

Birmingham, Alabama, United States

Jackson, Mississippi, United States

Newmarket, Ontario, Canada

Dallas, Texas, United States

Lynchburg, Virginia, United States

Jonesboro, Arkansas, United States

Pittsburgh, Pennsylvania, United States

Jacksonville, Florida, United States

Columbus, Ohio, United States

Pensacola, Florida, United States

Boston, Massachusetts, United States

Mobile, Alabama, United States

Walnut Creek, California, United States

Honolulu, Hawaii, United States

Indianapolis, Indiana, United States

Louisville, Kentucky, United States

Albuquerque, New Mexico, United States

Cincinnati, Ohio, United States

Philadelphia, Pennsylvania, United States

Chandler, Arizona, United States

Detroit, Michigan, United States

Janesville, Wisconsin, United States

Ventura, California, United States

Rock Hill, South Carolina, United States

Dallas, Texas, United States

Springfield, Illinois, United States

Lanham, Maryland, United States

Poughkeepsie, New York, United States

Miami, Florida, United States

Lansing, Michigan, United States

Midlothian, Virginia, United States

Saint Matthews, Kentucky, United States

Golden, Colorado, United States

Winter Haven, Florida, United States

Richmond, Virginia, United States

Edmonton, Alberta, Canada

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials